Quantitative Brain Amyloid PET Imaging-Technical Considerations

Thursday, November 17, 2022

08:30 AM EST to 5:00 PM EST

Hybrid Workshop

Objectives

This workshop aims to evaluate the role of quantitative positron emission tomography (PET) measures of amyloid deposition in the brain.

Welcome and Introductions

8:30am - 8:45am  Venkata Mattay, FDA; Munir Ghesani, SNMMI; Sue Bunning, MITA; Alessandra Rovescalli, NIA

Session I: Quantitative Brain Amyloid PET Imaging: Background

Moderator: William Jagust, University of California, Berkeley

8:45am - 8:55am  Introductory Comments

8:55am - 9:20am  Brain Amyloid PET: Overview of Clinical and Investigational Uses
• Reisa Sperling, Massachusetts General Hospital

9:20am - 9:45am  Characteristics of Brain Amyloid Tracers: Impact on Quantification
• Victor Villemagne, University of Pittsburgh

9:45am - 10:30am  Session I Panel
• Gil Rabinovici, University of California, SF
• Jonathan McConathy, SNMMI
• Phillip Kuo, University of Arizona

10:30am – 10:45am  Break
Session II: Products for Brain Amyloid Imaging

Moderators: Daniel Krainak and Venkata Mattay, FDA

10:45am - 11:00am  Regulatory Perspectives on Technical Characteristics of Drugs for Brain Amyloid PET
• Venkata Mattay, FDA

11:00am – 11:15am  Regulatory Perspectives on Devices for Brain Amyloid PET Quantitation
• Daniel Krainak, FDA

11:15am - 11:35am  Amyloid Quantitation Methodologies
• Susan Landau, University of California, Berkeley

11:35am - 12:15pm  Session II Panel
• C. David Cooke, Syntermed
• Johan Lilja, Hermes Medical
• Satoshi Minoshima, University of Utah
• Jon Piper, MIM Software Inc
• Marcus Steward, Siemens Medical Solutions

12:15pm - 1:15pm  Lunch

Session III: Quantitative Brain Amyloid PET Imaging Methodology, Metrics, Analytical Validity

Moderator: Daniel Krainak, FDA

1:15pm – 1:45pm  Semi-Quantitative and Quantitative Metrics
• Julie Price, Harvard University

1:45pm – 2:15pm  Variability in Quantitative Brain Amyloid PET Metrics
• Juan Domingo Gispert, Universitat Pompeu Fabra

2:15pm – 2:45pm  Session III Panel
• Juan Domingo Gispert, Universitat Pompeu Fabra
• Roger Gunn, Imperial College London
• Julie Price, Harvard University
• Victor Villemagne, University of Pittsburgh

2:45pm – 3:00pm  Break

Moderator: Sue-Jane Wang, FDA

3:00pm – 3:20pm
Evaluation of Qualitative and Quantitative Imaging: Implications for Diagnostic Imaging Drug Labeling
• Sue-Jane Wang, FDA

3:20pm – 4:00pm
Industry and Academic Perspectives on Brain Amyloid PET
• Val Lowe, Mayo Clinic
• Gill Farrar, GE Healthcare
• Andrew Stephens, Life Molecular Imaging
• Mark A. Mintun, Avid Radiopharmaceuticals and Eli Lilly and Company

4:00pm – 4:10pm
Patient’s Perspective – Patient Advocacy Group
• Maria C. Carrillo, Alzheimer’s Association

4:10pm – 4:55pm
Session IV Panel
• Tammie Benzinger, Washington University
• Gregory Klein, Roche
• Jonathan McConathy, SNMMI
• Mark Mintun, Avid Radiopharmaceuticals and Eli Lilly and Company
• Stephen Salloway, Brown University
• Reisa Sperling, Massachusetts General Hospital

4:55pm – 5:00pm
Closing Remarks, Adjournment
Louis Marzella, FDA